Uncategorized

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

by Business Wire • 2020/10/28 • 0 Comments

LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit SDS in Ongoing Phase I/I FOCUS Trial.

Full Story →

← Scripps Research scientists uncover potential new strategy for treating eye diseases

Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries →

Post navigation